The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Discovery of (1 R ,5 S )- N -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( S )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( S )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection
Open accessAbstract
Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide. Currently the only therapeutic regimens are subcutaneous interferon-alpha or polyethylene glycol (PEG)-interferon-alpha alone or in combination with oral ribavirin. Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virological response. Herein, the SAR leading to the discovery of 70 (SCH 503034), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clinical trials in human beings for the treatment of hepatitis C viral infections is described. X-ray structure of inhibitor 70 complexed with the NS3 protease and biological data are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
N-methoxy-n-methylamides as effective acylating agents
Nahm, S., & Weinreb, S. M. (1981) · Tetrahedron Letters · doi:10.1016/s0040-4039(01)91316-4 · Cited by 1,798
The Utility of Phosphonate Carbanions in Olefin Synthesis
Wadsworth, W. S., & Emmons, W. D. (1961) · Journal of the American Chemical Society · doi:10.1021/ja01468a042 · Cited by 1,401
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends
Wasley, A., & Alter, M. J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9506 · Cited by 979
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis
Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432302 · Cited by 874
Unravelling hepatitis C virus replication from genome to function
Lindenbach, B. D., & Rice, C. M. (2005) · Nature · doi:10.1038/nature04077 · Cited by 820
Cited by
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
Marsault, E., & Peterson, M. L. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1012374 · Cited by 843
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Organic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Zhang, L., Lin, D., Kusov, Y., Nian, Y., Ma, Q., Wang, J., von Brunn, A., Leyssen, P., Lanko, K., Neyts, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01828 · Cited by 568
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Talele, T., Khedkar, S., & Rigby, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232251 · Cited by 407
The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies
Pawlotsky, J., Chevaliez, S., & McHutchison, J. G. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.116 · Cited by 325
Njoroge, F. G., Chen, K. X., Shih, N.-Y., & Piwinski, J. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700109k · Cited by 266
Self-citationHepatitis C virus NS3/4a protease inhibitors
McCauley, J. A., & Rudd, M. T. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.015 · Cited by 120
Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor
Arasappan, A., Bennett, F., Bogen, S. L., Venkatraman, S., Blackman, M., Chen, K. X., Hendrata, S., Huang, Y., Huelgas, R. M., Nair, L., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml9000276 · Cited by 102
Self-citationSelective irreversible inhibition of a protease by targeting a noncatalytic cysteine
Hagel, M., Niu, D., St Martin, T., Sheets, M. P., Qiao, L., Bernard, H., Karp, R. M., Zhu, Z., Labenski, M. T., Chaturvedi, P., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.492 · Cited by 95
Metadata
- Authors
- Venkatraman, S., Bogen, S. L., Arasappan, A., Bennett, F., Chen, K., Jao, E., Liu, Y.-T., Lovey, R., Hendrata, S., Huang, Y., Pan, W., Parekh, T., Pinto, P., Popov, V., Pike, R., Ruan, S., Santhanam, B., Vibulbhan, B., Wu, W., Yang, W., Kong, J., Liang, X., Wong, J., Liu, R., Butkiewicz, N., Chase, R., Hart, A., Agrawal, S., Ingravallo, P., Pichardo, J., Kong, R., Baroudy, B., Malcolm, B., Guo, Z., Prongay, A., Madison, V., Broske, L., Cui, X., Cheng, K.-C., Hsieh, Y., Brisson, J.-M., Prelusky, D., Korfmacher, W., White, R., Bogdanowich-Knipp, S., Pavlovsky, A., Bradley, P., Saksena, A. K., Ganguly, A., Piwinski, J., Girijavallabhan, V., & Njoroge, F. G.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2006-09-07
- Volume
- 49
- Issue
- 20
- Pages
- 6074-6086
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1995778111
- Cited by
- 281
- References
- 19
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.